Resolution of Metastatic Subungal Eccrine Porocarcinoma Treated with Intralesional Interleukin-2

Ashley Drohan; Jennifer Melvin; Joanne Murphy; Carman Giacomantonio; Lucy Helyer

doi:10.3390/curroncol28010024

Resolution of Metastatic Subungal Eccrine Porocarcinoma Treated with Intralesional Interleukin-2

Curr Oncol. 2020 Dec 30;28(1):220-225. doi: 10.3390/curroncol28010024.

Authors

Ashley Drohan¹, Jennifer Melvin², Joanne Murphy³, Carman Giacomantonio⁴, Lucy Helyer⁴

Affiliations

¹ QEII Health Sciences Centre, Division of General Surgery, Dalhousie University, 1276 South Park St., Halifax, NS B3H 2Y9, Canada.
² Department of Medical Oncology, Dalhousie University, QEII Bethune Building, 1276 South Park St., Halifax, NS B3H 2Y9, Canada.
³ Department of Pathology, Dalhousie University, Halifax, NS B3H 4R2, Canada.
⁴ Department of Surgery, Dalhousie University, Halifax, NS B3H 2Y9, Canada.

Abstract

Eccrine porocarcinoma is a rare aggressive cutaneous malignancy. Complete surgical excision is the standard of care, although there are high rates of local and distant recurrence. We present a unique case of locally recurrent and metastatic subungal porocarcinoma successfully treated with intralesional interleukin-2.

Keywords: immunotherapy; interleukin-2; porocarcinoma.

Publication types

Case Reports

MeSH terms

Eccrine Porocarcinoma* / drug therapy
Humans
Interleukin-2
Neoplasm Recurrence, Local
Sweat Gland Neoplasms* / drug therapy

Substances

Interleukin-2